Biocon director expects DCGI to approve Oxford-AstraZeneca Covid-19 vaccine in emergencies
Biocon Chief Executive Kiran Mazumdar-Shaw said Tuesday that drug regulator DCGI is expected to grant an Emergency Use Authorization (EUA) for Oxford-AstraZeneca’s Covid-19 vaccine as soon as it gets approval from the UK Medicines and Health Products Regulatory Agency.
“100 million doses by January,” Adar Poonawalla says of the Oxford vaccine; hopefully DCGI will administer USA immediately after MHRA in December to start vaccination in India, which is the need of the moment, “Mazumdar-Shaw said in a tweet.
On Monday, Poonawalla had said that by January, the Serum Institute will have 100 million doses. It already has 40 million doses.
He had also expressed his happiness at the announcement by major pharmaceuticals AstraZeneca that its Covid-19 vaccine candidate has been found to be 70 percent effective on average.
Serum is conducting clinical trials of the Covid-19 vaccine candidate from the University of Oxford-AstraZeneca in India.
On Monday, AstraZeneca had said that one dosing regimen showed a 90 percent vaccine efficacy when the vaccine was given as a half dose followed by a full dose at least one month apart, while another dosing regimen showed a 62 percent efficacy when given in two full doses at least one month apart.
“Combined analysis of both dosage regimens resulted in an average efficacy of 70 percent,” he had said.
AstraZeneca also said it is rapidly advancing manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. “The vaccine can be stored, transported and handled under normal refrigeration conditions for at least six months and administered within existing healthcare settings,” he added.
India saw 37,975 new coronavirus infections in one day, bringing the country’s number of Covid-19 cases to 91.77 lakh, while recoveries exceeded 86 lakh, according to updated Union Ministry of Health data. on Tuesday. PTI AKT ANU ANU